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Osteoporosis is a skeletal disease, characterized by a thinning of the bone (loss 
of bone mass), accompanied by a deterioration of its internal architecture that com-
promises its resistance, producing a greater fragility of the bones and an increased 
risk of fractures. The most affected bones are especially those of the spine and hip, 
although any bone in the body can be involved. As the main risk factor for suffering 
bone fragility fractures, which increases with age, it is an important public health 
problem that has undoubted social, health and economic repercussions; but above 
all it causes pain, functional limitation and severe alteration in people’s quality 
of life.
The World Health Organization (WHO) defines it mainly in women as “the 
presence of a bone mineral density (BMD) less than or equal to 2.5 standard 
deviations below the average bone mass of healthy 20-year-olds”, which is carried 
performed using a specific radiological test, called bone mineral densitometry. 
Since bone loss often occurs without symptoms, osteoporosis is often considered a 
“silent disease” that can occur in both sexes and increases with age. As bone tissue 
deteriorates, together with the architecture changes, the bone becomes so weak, 
that a relatively minor bump or fall, causes a vertebra to fracture or break. That is, 
the clinical manifestations of osteoporosis appear as a consequence of its complica-
tions, which are spontaneous fractures or after minimal trauma. Many environmen-
tal factors are involved in their onset [1].
However, there is a risk of considering that the loss of bone mass, causes only 
musculoskeletal pain. Women are more susceptible to suffering from bone frac-
tures, as direct consequences of this disease, due to the fact that faced with a cal-
cium deficiency in the diet, together with a vitamin D deficiency, during pregnancy 
and lactation, the body goes to diminish the reserves of calcium in the bone, which 
is the cause of gradual loss of bone mass. For this reason, its appearance is later 
and more frequently in amenorrheic or post-menopausal women, who also have a 
decrease in the production of estrogens by the ovaries and other hormonal deficien-
cies that affect metabolism in the bone. Factors that increase the risk of developing 
osteoporosis are calcium and vitamin D deficiencies due to malnutrition, sedentary 
life or lack of physical activity, and tobacco and/or alcohol consumption. Other 
secondary causes have been reported, such as celiac disease, monoclonal gammopa-
thy of uncertain origin, chronic renal failure, diabetes mellitus, and renal tubular 
acidosis. Some epigenetic factors can be associated [2].
The best strategy for treating osteoporosis, is the prevention. Bone, or bone 
tissue, is a very dynamic living tissue throughout life, which is constantly formed 
(ossification), grows and remodels (bone turnover). For these processes (forma-
tion, growth and remodeling), important for the integrity or strength of the 
bone, hormonal activities, certain nutrients (calcium, phosphorus, magnesium, 
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vitamin D, vitamin K) and physical activity take part. Therefore, they are recog-
nized as factors that play an important role in the prevention and treatment of 
osteoporosis. You have to get a good BMD and maintain it throughout your life. 
For this, it is necessary to achieve optimal bone formation in the youngest and 
then avoid loss of bone mass in adulthood and old age.
To achieve these goals, it is necessary to carry out a diet that provides the essen-
tial nutrients for the formation, growth and maintenance of bones. It is important 
to guarantee the consumption of the daily needs or minimum requirements of 
Calcium (1300 mg/day), Phosphorus (1250 mg/day), Magnesium (420 mg/day) 
and Vitamin D (20 mcg/day equivalent to 800 IU/day), through normal nutrition 
(daily consumption of foods that contain these nutrients) or supplementation. 
Perform appropriate physical exercise for each age through frequent outdoor activ-
ity, which ensures prudent sun exposure, for the synthesis of vitamin D in the skin, 
but avoiding overexposure, due to the risks it has on skin health [3–5].
2. Classification
Taking into account the causes that produce it, osteoporosis can be classified as 
primary and secondary.
2.1 Primary or involutive
It is the most common type of osteoporosis. This diagnosis is established after 
evaluating the patient, when the cause/s that can be related, are not found. In turn, 
primary osteoporosis can in turn be subdivided into juvenile, postmenopausal, 
age-related, and idiopathic forms.
2.2 Secondary osteoporosis
When the loss of bone mass is caused by another disease, or by the use of 
particular drugs. Fractures occur most frequently at the level of the hip bones, 
vertebrae of the spine, and wrist. Vertebral fractures can cause loss of height of the 
spine as a whole and deformity of the rib cage.
Depending on the results obtained in BMD, the results can be classified accord-
ing to the T scale, which refers to the mean bone density of the healthy population 
of the same sex and 20 years of age in the following categories:
2.3 Normal
When bone mineral density is greater than −1 standard deviation (SD) on the 
T scale.
2.4 Osteopenia
When the BMD presents a standard deviation between 0 to −1, on the T scale. 
This variety is not included in osteoporosis and generally does not require drug 
treatment.
2.5 Osteoporosis
If bone mineral density is less than −2.5 standard deviations on the T scale.
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2.6 Established osteoporosis
When there is osteoporosis and it has caused a fracture [6, 7].
3. Epidemiology
Osteoporosis and its related complications, are one of the main health problems 
in the world. This disease is estimated to affect at least to 200 million of women 
globally and is a major cause of morbidity and mortality. Among North American 
postmenopausal white women, 57% are osteopenic and 30% osteoporotic, and 
from the age of 80 ahead, 27% of women present osteopenia and 70% osteoporosis, 
with a large increase in the latter.
It is reported that approximately 40% of white US women and 13% of white US 
men in their 50s will experience at least one brittle bone fracture in their lifetime. 
It is also estimated that 1 in 3 women and 1 in 12 men over the age of 50 suffer from 
osteoporosis. And it is responsible for millions of fractures annually, many of which 
include the lumbar vertebrae [8, 9].
4. Etiology
The bones of the body are subjected to continuous remodeling through processes 
of formation and reabsorption, they also serve as the body’s calcium reservoir. From 
the age of 35, the loss of bone mass begins. Multiple diseases or sedentary lifestyles, 
can increase the bone loss causing osteoporosis at an earlier age.
The main mechanisms that cause osteoporosis are: 1/. Lack of sufficient bone 
mass, during the growth process. 2/. Excessive bone resorption mediated by osteo-
clasts. 3/. Inadequated new bone formation by osteoblasts, during the continuous 
process of bone renewal.
Menopause is the main cause of osteoporosis in women, due to the decrease 
in the production of estrogen hormones, which are reduced by physiologi-
cal menopause or by surgical removal of the ovaries, causing rapid bone loss. 
Women, especially Caucasian and Asian, have lower bone mass than men. Bone 
loss results in decreased bone strength, easily leading to wrist, spine, and hip 
fractures.
However, there are a considerable number of causes of osteoporosis at any age 
that are not usually recognized or valued, but that can be identified if the patient 
undergoes an appropriated evaluation. Among them, the most common are 
undiagnosed Celiac Disease, due to the fact that it occurs frequently in a subclini-
cal or asymptomatic way, and in people with negative antibody tests, untreated 
Non-Celiac Gluten Sensitivity, Monoclonal Gammapathy of uncertain significance, 
patients with Chronic Renal Failure, Diabetes Mellitus, and with Renal Tubular 
Acidosis.
In people with Celiac Disease or Non-Celiac Gluten Sensitivity without diagnos-
ing, or following a gluten-free diet, the causes of both osteoporosis and osteopenia, 
are not limited to the existence of possible nutritional deficiencies, but may be due 
to processes inflammatory or autoimmune diseases in which the consumption of 
gluten can cause the development of autoantibodies.
The causes of secondary osteoporosis can be divided into several groups: endo-
crinological, gastrointestinal, by drugs, the presence of prolonged amenorrhea, or 
by various malignant tumor processes.
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4.1 Endocrinological
Hyperthyroidism Hyperparathyroidism, Cushing’s Syndrome, Type 1 
Diabetes (insulin-dependent), Addison’s disease, Sarcoidosis, Hypogonadism, 
Gigantism.
4.2 Gastrointestinal
Celiac disease, Ulcerative Colitis, Crohn’s disease, Liver disease (especially 
Primary Biliary Cholangitis), Gastrectomy and Intestinal resection.
4.3 Drugs
The most frequently implicated are corticosteroids, lithium salts and some  
anti-epileptics, among others.
4.4 Various processes
Prolonged malnutrition, Large intestinal resections, Chronic alcoholism, 
Rheumatoid arthritis, Prolonged immobilization, others [10].
5. Clinical symptoms
Osteoporosis usually does not cause any symptoms. For this reason, it has been 
called the “silent epidemic”. However, the error of considering that the loss of 
bone mass causes musculoskeletal pain is widespread. and patients are frequently 
referred to a specialist for this reason with suspected osteoporosis, especially pre-
menopausal women or in young people.
The main clinical manifestations of osteoporosis are due to its complications, 
such as fractures, which mainly occur in the spine, wrists and hips. They are 
caused by minor trauma, such as a simple fall. This is why they are called  
“brittle fractures.” They are usually classified broadly as “vertebral” and  
“non-vertebral.” They produce the same symptoms as other fractures in the  
same location and are characterized by the presence of pain, deformity and 
functional impotence.
Vertebral fractures are the most frequent. They appear as a result of an effort, 
when carrying weights or bending over, but they can also appear spontaneously, 
without finding an apparent reason. They are typically accompanied by acute  
pain, which increases with movement and decreases with rest. The intensity of the 
pain usually decreases after the first 2–3 weeks and disappears in some cases after 
more than two years.
However, about two-thirds of vertebral fractures do not cause symptoms 
and can only be verified by radiography of the thoracic or lumbar spine. In some 
patients, as a consequence of structural alterations of the spine, instability of the 
spine may develop which is accompanied by muscle contractures and ligament 
tension, which can cause chronic pain.
The most serious fractures are those of the hip, usually as a result of a fall. 
Although there is no data to confirm this, the popular belief has spread that as a 
result of significant osteoporosis, the patient fractures the hip while standing and 
then falls, although this is not always the case [11].
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6. Diagnosis
Osteoporosis is diagnosed by the evaluation of the findings of bone mineral 
densitometry test, which measures the amount of bone mass in the skeleton.
Its measurement is usually carried out at the level of the central skeleton (lum-
bar spine and/or neck of the femur) using specific radiology equipment (dual-DXA 
radiological densitometry). In the event that the central skeleton cannot be mea-
sured due to the existence of advanced osteoarthritis, fractures or prostheses that 
would invalidate the result, densitometry can be performed in such cases on the 
forearm or heel with other equipment (peripheral measurement DXA or quantita-
tive ultrasonometry).
To evaluate the possible secondary causes of osteoporosis, basic and comple-
mentary tests are carried out; the latter, depending on the clinical suspicion:
7. Basic tests
1/. Comprehensive, complete and detailed medical history. 2/. Complete blood 
count with count of the three series, leukocyte formula and sedimentation rate. 
3/. Coagulation study, to see if it is normal, or is accompanied by some alterations. 
4/. Complete Biochemistry study, including serum levels of calcium, phosphorus, 
creatinine, alkaline phosphatase, sodium, and potassium. 5/. Serum levels of TSH 
and vitamin D. 6/. Total protein and albumin levels, with associated proteinogram 
to detect possible presence of gammapathies [12].
8. Supplementary tests
a. Determination of serum levels of parathormone, bone-specific alkaline phos-
phatase, prolactin and immunoglobulins.
b. Quantification of IgA, IgG and IgM immunoglobulins.
c. Determination of celiac disease antibodies (anti-transglutaminase IgA)
d. Biochemical markers of bone remodeling, such as the C-terminal propeptide of 
type I procollagen.
e. Fasting serum T3, T4 and plasma cortisol levels.
f. 24-hour urine study, to quantify total calcium and phosphorus elimination in 
one total day
g. Gastroscopy with taking duodenal biopsies to study celiac disease
h. Determination of insulin growth factor type 1 (in cases of anorexia and 
diabetes)
i. Fibroblast growth factor 23 levels
j. Bone biopsies samples, only when considered necessary in special cases
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9. Treatments
The first step before recommending a treatment is to evaluate the patient for 
determining if its case belongs to primary or secondary osteoporosis, in order to 
detect the diseases that cause it, some of which often go unnoticed. If the causative 
disease is adequately treated and low bone density for age persists, treatment will 
depend on the dynamics of the bones.
The general guidelines are based on recommending an adequate amount of calcium 
in the diet, the practice of physical exercise and the use of medications that contribute 
to the maintenance or increase of bone mass. The main drugs used are calcium salts 
alone or associated with vitamin D, bisphosphonates, strontium ranelate, raloxifene 
and teriparatide, denosumab, calcitonin and hormonal treatment with estrogens.
Bisphosphonates are the most widely used group of drugs. Within these drugs 
are alendronic acid (alendronate), risedronate and ibandronate.
10. Diet, calcium and vitamin D supplements
Calcium is necessary to support bone growth, bone repair, and for maintaining 
the bone strength and is one of the main pillars of osteoporosis treatment. Calcium 
intake recommendations vary depending on the country and age. For individuals 
at high risk of osteoporosis over the age of 50, the amount recommended by the US 
Health Agencies is 1,200 mg per day. Calcium supplements can be used to increase 
dietary intake, and their absorption is optimized by taking several small (500 mg or 
less) dosages throughout the day.
The role of calcium in preventing and treating osteoporosis is unclear because 
some populations with extremely low intakes of calcium have low rates of bone 
fracture, and others with a high intake of calcium through both milk and its deriva-
tives have a lot of bone fracture.
Other factors, such as protein intake, salt, vitamin D, exercise, sun exposure, 
also influence bone mineralization, making calcium intake one of many factors in 
the development of osteoporosis. Some studies show that a large intake of vitamin 
D, reduces the risk of fractures. However, other researchers have not confirmed 
these conclusions, so this aspect of treatment is a matter of debate [13].
Vegan diets can cause significant nutritional deficiencies, including calcium and 
vitamin D. These people tend to have low bone mass. The European Prospective 
Study on Cancer and Nutrition (EPIC, published in 2007) concludes that vegans 
have a 30% higher risk of bone fractures, than meat, fish and other subtypes of veg-
etarians, probably due to their considerably lower average consumption of calcium, 
although those who consume adequate amounts of this mineral have the same risk 
of fracture as the general population.
The risks of nutritional deficiencies and serious health consequences are espe-
cially important during pregnancy, in babies and in children. These deficiencies 
can only be prevented by choosing fortified foods or taking regular dietary supple-
ments, for which personalized education and evaluation by nutrition professionals 
is essential. Both parents and adolescents may lack the necessary knowledge for 
proper vegan diet planning.
11. Physical exercise
Multiple studies confirm that maintaining an ideal weight and periodical per-
forming aerobic physical exercise or resistance exercises, can maintain or increase 
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bone density (DO) in postmenopausal women. Many researchers have evaluated 
which types of exercise are the most effective in improving BD and other measures 
of bone quality, however results vary [14].
One year of regular exercise increases bone density and proximal tibial moment 
of inertia in normal postmenopausal women. Walking, gymnastic training, step-
ping, jumping, endurance, and strength exercises result in a significant increase 
in bone densities from the second to fourth lumbar vertebrae in postmenopausal 
osteopenic women. Other benefits of physical exercise include improved balance 
and reduced risk of falls.
12. Bisphosphonates
In confirmed osteoporosis, this group of drugs belong to the first line of treat-
ment and they are the most widely used and those with the most experience of use. 
The most commonly used are alendronic acid, 10 mg per day, or 70 mg per week, 
risedronic acid, 5 mg /day or 35 mg/week, ibrandonic acid 150 mg once a month, or 
zoldronic acid, 5 mg once a year intravenously.
Osteoporosis is caused by the decrease in the tissue that forms bone, both in the 
proteins that make up its matrix or structure and in the mineral salts of calcium it con-
tains. As a consequence, the bone is less resistant and more fragile than normal [15].
Oral bisphosphonates have a relatively low absorption, and is recommended that 
food or liquids should not be ingested within 30 minutes of administration. They 
can cause side effects such as esophagitis and, rarely, jaw osteonecrosis. Zoledronic 
acid administered once a year intravenously does not present the problems of oral 
intolerance, but it frequently causes as a side- effect a picture of joint pain and fever 
that is not serious.
13. Teriparatide
It is an analog of human parathyroid hormone that is made up of a sequence 
of 34 amino acids, corresponding to the active fragment of the natural hormone. 
It is therefore a new bone-forming drug and is indicated in the treatment of 
osteoporosis.
It is used primarily in patients with established osteoporosis and a history of 
fractures, with particularly low bone mass, or with various risk factors for fractures. 
A daily injection of 20 micrograms is given subcutaneously. In some countries its 
use is only authorized if bisphosphonates have not been effective, or are contra-
indicated. Teriparatide is contraindicated in various circumstances, such as preg-
nancy, Paget’s disease, hyperparathyroidism, and malignant tumors involving the 
bone [16].
14. Strontium Ranelate
It is an oral treatment alternative. It is effective in preventing vertebral fracture, 
but not hip fractures. It works by stimulating the proliferation of osteoblasts and 
also inhibits the proliferation of osteoclasts.
It is administered orally at a dose of 2 g daily. It does not have the side effects of 
bisphosphonates, as it does not cause gastric or esophageal symptoms. However, 
it has been shown to increase the risk of venous thromboembolism and can cause 
some serious dermatological reactions [17].
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15. Hormone replacement therapy
15.1 Estrogens
Although it is known that estrogen treatment can be effective in stopping the 
loss of mineral content from bone in women after menopause, its administration as 
a treatment for osteoporosis is not currently recommended, due to the possibility 
of serious side effects and the existence of other safer alternatives. For this reason, 
estrogen therapy, as a hormonal treatment for menopause, is not recommended for 
the treatment of osteoporosis [18].
15.2 Testosterone
In men with testicular hypofunction, the administration of testosterone 
improves bone quantity and quality. However, there are no studies on its effects in 
reducing fractures or in men with normal testosterone levels [19].
15.3 Raloxifene
It is a selective estrogen receptor modulator. Drugs of this therapeutic group, 
bind to specific receptors on cells, simulating the activity of estrogens in certain 
tissues. Raloxifene acts on bone by decreasing osteoclast bone resorption and mak-
ing vertebral fracture less likely. However, it is not effective in trying to reduce the 
incidence of hip fractures [20].
15.4 Denosumab
It is a drug that belongs to the group of biological agents, made up of monoclonal 
antibodies. In June 2010, its use was approved in the USA by the FDA to be used in 
the treatment of osteoporosis in post-menopausal women at high risk of fractures. 
Its mechanism of action is based on binding to a cellular receptor called RANKL, 
preventing its activation, which causes an inhibition in the formation of osteoclasts 
and their functionality. Osteoclasts are cells that are involved in the loss of bone 
mass and therefore favor the appearance of fractures [21, 22].
15.5 Prognosis
Patients with osteoporosis have an increased mortality rate, due to the greater 
likelihood of fractures occurring. The highest rate associated with osteoporosis is 
related to hip fractures, with an approximate mortality of 13.5% six months after 
they occur and 20–30% during the first year, which means that the risk of death, 
increases 2 to 10 times, higher than expected, in the population with similar char-
acteristics. The causes of death are diverse and in many cases, they are not directly 
related to the presence of fractures.
The bad consequences of hip fractures are not limited to their hospital treat-
ment, but to the deterioration of the quality of life, due to the residual disability 
that they entail. They can cause decreased mobility and the development of 
various complications, such as deep vein thrombosis, pulmonary embolism, and 
pneumonia.
At least 13% of the people who suffer them, need permanent help to be able to 
move. Vertebral fractures have less impact on mortality than hip fractures, but they 
can lead to thoracic and abdominal deformities, causing chronic pain that is difficult 
to control. Multiple vertebral fractures can lead to the appearance of significant 
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lordosis and kyphosis of the spine, with the consequent increase in pressure on inter-
nal organs, which can decrease the respiratory capacity of affected subjects [23, 24].
Osteoporotic fractures are generally associated with a significant decrease in 
health-related quality of life [25].
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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